Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, Zhang Z, Dietz AB, Porrata LF, Novak AJ, Liang AB, Yang ZZ, Ansell SM.

Blood Cancer J. 2015 Jul 31;5:e328. doi: 10.1038/bcj.2015.56.

2.

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.

Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM.

Blood Cancer J. 2015 Feb 20;5:e281. doi: 10.1038/bcj.2015.1.

3.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM.

Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

4.

Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.

Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, Ristow KM, Yang ZZ, Nowakowski GS, Feldman AL, Cerhan JR, Novak AJ, Ansell SM.

Clin Cancer Res. 2014 Jun 1;20(11):2862-72. doi: 10.1158/1078-0432.CCR-13-2367. Epub 2014 Apr 11.

5.

TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ, Ansell SM.

Leukemia. 2014 Sep;28(9):1872-84. doi: 10.1038/leu.2014.84. Epub 2014 Feb 26.

6.

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.

Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ.

Blood Cancer J. 2014 Feb 14;4:e183. doi: 10.1038/bcj.2014.4.

7.

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, Ristow K, Habermann TM, Thomas D, Ziesmer SC, Wellik LE, Lanigan TM, Witzig TE, Pittelkow MR, Bailey NG, Hristov AC, Lim MS, Ansell SM, Wilcox RA.

Blood. 2014 May 8;123(19):3007-15. doi: 10.1182/blood-2013-12-544809. Epub 2014 Feb 4.

8.

Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.

Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Novak AJ, Ansell SM.

Blood. 2014 Feb 13;123(7):1055-8. doi: 10.1182/blood-2013-08-521963. Epub 2013 Dec 11.

9.

B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.

Secreto F, Manske M, Price-Troska T, Ziesmer S, Hodge LS, Ansell SM, Cerhan JR, Novak AJ.

Leuk Lymphoma. 2014 Aug;55(8):1884-92. doi: 10.3109/10428194.2013.862619. Epub 2014 Feb 24.

10.

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.

Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM.

Clin Cancer Res. 2013 Dec 15;19(24):6812-9. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18.

11.

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Fermé C, Dogan A, Macon WR, Audouin J, Cerhan JR, Salles G.

Cytokine. 2013 Nov;64(2):523-31. doi: 10.1016/j.cyto.2013.08.002. Epub 2013 Sep 3.

12.

MR elastography derived shear stiffness--a new imaging biomarker for the assessment of early tumor response to chemotherapy.

Pepin KM, Chen J, Glaser KJ, Mariappan YK, Reuland B, Ziesmer S, Carter R, Ansell SM, Ehman RL, McGee KP.

Magn Reson Med. 2014 May;71(5):1834-40. doi: 10.1002/mrm.24825. Epub 2013 Jun 25.

13.

Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma.

Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Yates NR, Secreto FJ, Hodge LS, Witzig TE, Novak AJ, Ansell SM.

PLoS One. 2013;8(3):e59456. doi: 10.1371/journal.pone.0059456. Epub 2013 Mar 15.

14.

Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor.

Hussain S, Feldman AL, Das C, Ziesmer SC, Ansell SM, Galardy PJ.

Mol Cell Biol. 2013 Mar;33(6):1188-97. doi: 10.1128/MCB.01389-12. Epub 2013 Jan 7.

15.

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ.

Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.

16.

IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.

Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA, Novak AJ, Ansell SM.

Blood. 2012 Nov 1;120(18):3774-82. doi: 10.1182/blood-2012-03-419440. Epub 2012 Sep 13.

17.

t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.

Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, Ziesmer S, Secreto F, Fonseca R, Gupta M, Law M, Witzig TE, Dyer MJ, Dogan A, Cerhan JR, Novak AJ.

Blood. 2012 Nov 8;120(19):3949-57. doi: 10.1182/blood-2011-11-389908. Epub 2012 Sep 10.

18.

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ.

Am J Hematol. 2012 Sep;87(9):865-9. doi: 10.1002/ajh.23259. Epub 2012 Jun 3.

19.

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM.

J Clin Invest. 2012 Apr;122(4):1271-82. doi: 10.1172/JCI59806. Epub 2012 Mar 19.

20.

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.

Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, Ziesmer S, Dogan A, Witzig TE.

Blood. 2012 Mar 22;119(12):2844-53. doi: 10.1182/blood-2011-10-388538. Epub 2012 Feb 8.

21.

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.

Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE.

Leukemia. 2012 May;26(5):1046-52. doi: 10.1038/leu.2011.297. Epub 2011 Oct 21.

22.

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, Witzig TE, Fernandez-Zapico ME, Ansell SM.

Blood. 2011 Nov 17;118(20):5540-9. doi: 10.1182/blood-2011-04-351742. Epub 2011 Sep 14.

23.

Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.

Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ, Ansell SM.

Blood. 2011 Sep 8;118(10):2809-20. doi: 10.1182/blood-2011-03-340885. Epub 2011 Jun 30.

24.

GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Elsawa SF, Almada LL, Ziesmer SC, Novak AJ, Witzig TE, Ansell SM, Fernandez-Zapico ME.

J Biol Chem. 2011 Jun 17;286(24):21524-34. doi: 10.1074/jbc.M111.234146. Epub 2011 Mar 18.

25.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE.

Lancet Oncol. 2011 Apr;12(4):361-8. doi: 10.1016/S1470-2045(11)70062-6.

26.

Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.

Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, Morice WG, Gertz MA, Ansell SM.

Blood. 2011 May 12;117(19):e190-7. doi: 10.1182/blood-2010-12-326868. Epub 2011 Mar 17.

27.

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.

Hildebrand JM, Luo Z, Manske MK, Price-Troska T, Ziesmer SC, Lin W, Hostager BS, Slager SL, Witzig TE, Ansell SM, Cerhan JR, Bishop GA, Novak AJ.

J Exp Med. 2010 Nov 22;207(12):2569-79. doi: 10.1084/jem.20100857. Epub 2010 Nov 1.

28.

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.

Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB, Novak AJ, Witzig TE, Feldman AL, Pittelkow MR, Ansell SM.

Blood. 2009 Oct 1;114(14):2936-44. doi: 10.1182/blood-2009-05-220111. Epub 2009 Aug 11.

29.

Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.

Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM.

Cancer Res. 2009 Jul 1;69(13):5522-30. doi: 10.1158/0008-5472.CAN-09-0266. Epub 2009 Jun 9.

30.

Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, Ziesmer S, Liebow M, Macon WR, Dillon SR, Witzig TE, Cerhan JR, Ansell SM.

Cancer Res. 2009 May 15;69(10):4217-24. doi: 10.1158/0008-5472.CAN-08-4915. Epub 2009 Apr 21.

31.

A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.

Gupta M, Dillon SR, Ziesmer SC, Feldman AL, Witzig TE, Ansell SM, Cerhan JR, Novak AJ.

Blood. 2009 May 21;113(21):5206-16. doi: 10.1182/blood-2008-09-179762. Epub 2009 Mar 25.

32.

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.

Ansell SM, Novak AJ, Ziesmer S, Price-Troska T, LaPlant B, Dillon SR, Witzig TE.

Am J Hematol. 2009 Feb;84(2):71-3. doi: 10.1002/ajh.21328.

33.

A role for IFN-lambda1 in multiple myeloma B cell growth.

Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM.

Leukemia. 2008 Dec;22(12):2240-6. doi: 10.1038/leu.2008.263. Epub 2008 Oct 2.

34.

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells.

Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM.

Blood. 2007 Oct 1;110(7):2537-44. Epub 2007 Jul 5.

35.

Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.

Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM.

Cancer Res. 2006 Oct 15;66(20):10145-52.

36.

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC.

Haematologica. 2006 Mar;91(3):390-3. Epub 2006 Feb 17.

37.

Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.

Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM.

J Clin Oncol. 2006 Feb 20;24(6):983-7. Epub 2006 Jan 23.

PMID:
16432079
38.

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM.

Blood. 2006 Apr 1;107(7):2882-8. Epub 2005 Nov 22.

39.

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM.

Blood. 2004 Oct 15;104(8):2247-53. Epub 2004 Jul 13.

40.

Adenoma-specific alterations of protein kinase C isozyme expression in Apc(MIN) mice.

Klein IK, Ritland SR, Burgart LJ, Ziesmer SC, Roche PC, Gendler SJ, Karnes WE Jr.

Cancer Res. 2000 Apr 15;60(8):2077-80.

41.

Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer.

Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC.

J Endocrinol. 1999 Dec;163(3):495-504.

PMID:
10588823
42.

Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry.

Kurtin PJ, Hobday KS, Ziesmer S, Caron BL.

Am J Clin Pathol. 1999 Sep;112(3):319-29.

PMID:
10478136
43.

In vivo analysis of Fas/FasL interactions in HIV-infected patients.

Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, Roche P, Yagita H, Paya CV.

J Clin Invest. 1998 Jul 1;102(1):79-87.

44.

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

Dockrell DH, Badley AD, Villacian JS, Heppelmann CJ, Algeciras A, Ziesmer S, Yagita H, Lynch DH, Roche PC, Leibson PJ, Paya CV.

J Clin Invest. 1998 Jun 1;101(11):2394-405.

45.

Expression of nm23/nucleoside diphosphate kinase-A protein in endometrial carcinoma.

Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Harmsen WS, Ziesmer SC, Roche PC, Podratz KC.

Gynecol Oncol. 1997 Aug;66(2):238-45.

PMID:
9264569
46.

Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.

Baron AT, Huntley BK, Lafky JM, Reiter JL, Liebenow J, McCormick DJ, Ziesmer SC, Roche PC, Maihle NJ.

Hybridoma. 1997 Jun;16(3):259-71.

PMID:
9219036
47.

Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability.

Lim PC, Tester D, Cliby W, Ziesmer SC, Roche PC, Hartmann L, Thibodeau SN, Podratz KC, Jenkins RB.

Clin Cancer Res. 1996 Nov;2(11):1907-11.

48.

p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors.

Halling KC, Scheithauer BW, Halling AC, Nascimento AG, Ziesmer SC, Roche PC, Wollan PC.

Am J Clin Pathol. 1996 Sep;106(3):282-8.

PMID:
8816583
49.

Chronic increases in blood flow upregulate endothelin-B receptors in arterial smooth muscle.

Barber DA, Michener SR, Ziesmer SC, Miller VM.

Am J Physiol. 1996 Jan;270(1 Pt 2):H65-71.

PMID:
8769735
50.

Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory.

Dalrymple SJ, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ.

Neurosurgery. 1994 Dec;35(6):1036-44; discussion 1044-5.

PMID:
7885547

Supplemental Content

Loading ...
Support Center